{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:09:21Z","timestamp":1786986561703,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-2-0026"],"award-info":[{"award-number":["W81XWH-18-2-0026"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["P01HL147835"],"award-info":[{"award-number":["P01HL147835"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P42ES010337"],"award-info":[{"award-number":["P42ES010337"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","award":["UL1TR001442"],"award-info":[{"award-number":["UL1TR001442"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK120515"],"award-info":[{"award-number":["P30DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK124318"],"award-info":[{"award-number":["R01DK124318"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK121378"],"award-info":[{"award-number":["R01DK121378"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK061734"],"award-info":[{"award-number":["U01DK061734"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK106419"],"award-info":[{"award-number":["R01DK106419"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cgh.2021.03.005","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T01:53:46Z","timestamp":1615427626000},"page":"1209-1217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Treatment Candidacy for Pharmacologic Therapies for NASH"],"prefix":"10.1016","volume":"20","author":[{"given":"Ian A.","family":"Rowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.03.005_bib1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(16)30011-5","article-title":"Pathogenesis and novel treatment options for non-alcoholic steatohepatitis","volume":"1","author":"Wong","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.03.005_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","volume":"3","author":"Marshall","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cgh.2021.03.005_bib12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.03.005_bib13","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib15","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib18","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib19","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cgh.2011.01.023","article-title":"Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma","volume":"9","author":"Yasui","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.03.005_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/apt.14112","article-title":"Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients","volume":"46","author":"Sookoian","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.03.005_bib24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.cgh.2015.01.027","article-title":"Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis","volume":"13","author":"Arulanandan","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2021.03.005_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/tgh.2019.06.06","article-title":"Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis","volume":"4","author":"Wong","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib30","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.03.005_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.03.005_bib33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.03.005_bib34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2021.03.005_bib35","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","author":"Newsome","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.03.005_bib36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.03.005_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm.4453","article-title":"The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2021.03.005_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hep.30822","article-title":"Hepatocyte TNF receptor-associated factor 6 aggravates hepatic inflammation and fibrosis by promoting lysine 6-linked polyubiquitination of apoptosis signal-regulating kinase 1","volume":"71","author":"Wang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib42","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib43","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.30674","article-title":"MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of a stearoyl-coenzyme-A-desaturase-1 inhibitor (ARRIVE trial)","volume":"70","author":"Ajmera","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib44","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.03.005_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.03.005_bib46","first-page":"57","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1\u2014First International Study of Infarct Survival Collaborative Group","volume":"2","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.03.005_bib47","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.03.005_bib49","author":"Food and Health Administration"},{"key":"10.1016\/j.cgh.2021.03.005_bib51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib52","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib53","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cgh.2021.03.005_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.03.005_bib55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib56","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/MEG.0000000000001614","article-title":"High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis: a systematic review","volume":"32","author":"Roskilly","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib58","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.03.005_bib59","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib60","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib62","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.03.005_bib63","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","author":"Jung","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.03.005_bib64","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.03.005_bib65","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.005_bib66","doi-asserted-by":"crossref","first-page":"101167","DOI":"10.1016\/j.molmet.2021.101167","article-title":"Imaging biomarkers of NAFLD, NASH, and fibrosis","author":"Ajmera","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.cgh.2021.03.005_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31734","article-title":"Non-invasive tests to phenotype nonalcoholic fatty liver disease: sequence and consequences of arranging the tools in the tool box","author":"Vuppalanchi","year":"2021","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:54:22Z","timestamp":1778522062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1542356521002287"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.03.005","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Candidacy for Pharmacologic Therapies for NASH","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}